Mary Fidler to Cetuximab
This is a "connection" page, showing publications Mary Fidler has written about Cetuximab.
Connection Strength
0.048
-
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 12; 43(12):3875-3887.
Score: 0.048
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.